Phase II Sunitinib Prog Met AIPC

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
US Oncology Research
ClinicalTrials.gov Identifier:
NCT00599313
First received: January 11, 2008
Last updated: May 21, 2014
Last verified: May 2014
  Purpose

The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.


Condition Intervention Phase
Metastatic Prostate Cancer
Drug: Sunitinib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy

Resource links provided by NLM:


Further study details as provided by US Oncology Research:

Primary Outcome Measures:
  • Determination of progression-free survival (PFS) [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: March 2007
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sunitinib Malate
Sunitinib Malate (Sutent) (50 mg/day on Days 1-28 of 42-day cycles)
Drug: Sunitinib
50 mg/day orally each of Days 1-28 of each 6 week cycle
Other Names:
  • Sunitinib malate
  • Sutent

Detailed Description:

The following rationale can be made for a Phase II trial to evaluate sunitinib malate (Sutent) for the therapy of progressive metastatic androgen-independent prostate cancer (AIPC) following prior docetaxel chemotherapy. Since most patients with metastatic AIPC following prior chemotherapy clinically progress rapidly, we believe that achieving a 30% freedom from clinical progression (PFS) (not including PSA progression) at 12 weeks represents biologically active therapy. Sunitinib malate (Sutent) represents a tolerable and convenient form of therapy with the potential for improving outcomes in AIPC.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A patient will be eligible for inclusion in this study if he meets all of the following criteria:
  • Histologically confirmed, adenocarcinoma of the prostate
  • Stage IV(metastatic) disease, documented on CT, MRI, or X-ray
  • Progressive disease (PSA or clinical): PSA progression defined as baseline increase followed by any serial increase after 2 weeks; clinical progression by symptomatic or radiologic criteria.
  • An elevated PSA level of for patients progressing by PSA criteria is required
  • Currently on androgen ablation hormone therapy (an LHRH agonist or orchiectomy) with testosterone level <50ng/dL)
  • Has received 1 or 2 prior chemotherapy regimens (no more than 2). One prior regimen must be docetaxel.
  • Has an ECOG Performance Status (PS) 0-2
  • Is greater than 18 years of age
  • Meets protocol defined laboratory values
  • Has adequate cardiac function in the opinion of the Investigator
  • Has no uncontrolled arrhythmia or hypertension
  • Resolution of all acute toxic effects of prior chemotherapy or surgical procedures to NCI CTCAE Version 3.0 Grade less than 1, in the opinion of the Treating Physician
  • If fertile, patient has agreed to use an acceptable method of birth control to prevent pregnancy for the duration of the study and for a period of 2 months thereafter
  • Has signed a Patient Informed Consent Form
  • Has signed a Patient Authorization Form

Exclusion Criteria:

  • A patient will be excluded from this study if he meets any of the following criteria:
  • Has any disease other than that described in inclusion criterion #1
  • Had prior treatment with Sutent
  • Has not received prior docetaxel for the current disease
  • Has received any prior radionuclide therapy
  • Has received prior radiation to >50% of the bone marrow
  • Is receiving concurrent immunotherapy
  • Has a history of hypersensitivity to any of the components of Sutent: mannitol, croscarmellose sodium, povidone (K-25) and magnesium stearate as inactive ingredients. The orange gelatin capsule shells contain titanium dioxide, and red iron oxide. The caramel gelatin capsule shells also contain yellow iron oxide and black iron oxide. The printing ink contains shellac, propylene glycol, sodium hydroxide, povidone and titanium dioxide.
  • Has had significant bleeding in previous 4 weeks
  • Has had any of the following within the prior 6 months: severe/unstable angina, myocardial infarction, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident, transient ischemic attack, or pulmonary embolism
  • Is receiving concurrent bisphosphonate therapy; long-standing bisphosphonate therapy (initiated >8 weeks prior to registration) is acceptable. Bisphosphonates started within the prior 8 weeks will not be allowed since this may affect other study endpoints and render their interpretation difficult
  • Has received treatment with radiation therapy, surgery, chemotherapy, ketoconazole, corticosteroids, or an investigational agent within 4 weeks prior to registration, (6 weeks for radiation therapy, nitrosureas or Mitomycin C)
  • Has uncontrolled arrhythmia or hypertension
  • Has evidence of uncontrolled CNS involvement (previous radiation and off steroids is acceptable)
  • Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
  • Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
  • Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin), which could affect the diagnosis or assessment of any of the study drugs
  • Is unable to comply with requirements of study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00599313

  Show 45 Study Locations
Sponsors and Collaborators
US Oncology Research
Pfizer
Investigators
Principal Investigator: Guru Sonpavde, MD US Oncology Research
  More Information

No publications provided

Responsible Party: US Oncology Research
ClinicalTrials.gov Identifier: NCT00599313     History of Changes
Other Study ID Numbers: 05112, 2006-0012
Study First Received: January 11, 2008
Last Updated: May 21, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Sunitinib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors

ClinicalTrials.gov processed this record on July 20, 2014